INNOVATION IN PREVENTION AND TREATMENT OF ALLERGIC RHINITIS IN CHILDREN
DOI:
https://doi.org/10.46793/PP160728006ZKeywords:
Allergic rhinitis, prevention, treatment, childrenAbstract
Allergic rhinitis affects more than 500 million people worldwide and can be considered the leading chronic respiratory disorder because of its prevalence, impact on quality of life, economic importance, effects on work and school performance, as well as the association with asthma. The prevalence of allergic rhinitis is still increasing.Treatment options for AR (ARIA) are numerous and include: 1) patient education; 2) prevention of exposure to allergens and irritans from the environment; 3) pharmacological therapy; 4) immunotherapy. However, about 20% of patients treated under the proprositions clinical guide for AR haven̕t adequate control of symptoms and the therapy of AR remains a challenge for clinicians. Therefore, we should bear in mind the other therapeutic options, and improve the availability of immunotherapy and new modalities in the treatment of AR.
References
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens J, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration ith the World Health Organisation, GA(2)LEN and AllerGen). Allergy 2008;63 (suppl86):8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: casecontrol study. J Allergy Clin Immunol 2007; 120:3817. doi:10.1016/j.jaci.2007.03.034
Vandenplas O, D̕Alpaos V, Van Brussel P. Rhinitis and its impact on work. Curr Opin Allergy Clin Immunol 2008; 8:1459.
Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007;62:1057-63. doi: 10.1111/j.1398-9995.2007.01367.x
Pawankar R, Walkter Canonica G, MD, Holgate S, Lockey R. White Book on Allergy 2011-2012 Executive Summary. World Health Organization.
Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Primary Care Respiratory Journal 2008; 17(1): 7-18. doi:10.3132/pcrj.2008.00001
Small P, Kim H. Allergic Rhinitis. Allergy, Asthma & Clinical Immunology2011;7(Suppl 1):S3 doi: 10.1186/1710-1492-7-S1-S3
Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14. doi: 10.1111/j.1476-5381.2010.00907.x
Small P, Frenkiel S, Becker A, Boisvert P, Bouchard J, Carr S, Cockcroft D, Denburg J, Desrosiers M, Gall R, Hamid Q, Hébert J, Javer A, Keith P, Kim H, Lavigne F, Lemièr C, Massoud E, Payton K, Schellenberg B, Sussman G, Tannenbaum D, Watson W, Witterick I, Wright E, The Canadian Rhinitis Working Group: Rhinitis: A practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007; 36 (Suppl 1): S5-S27.doi: 10.1186/1710-1492-7-S1-S3
van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116-34. doi: 10.1034/j.1398-9995.2000.00526.x
Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002;23:391-8.
Quraishi MS, Jones NS, Mason JDT. The nasal delivery drugs. Clinical Otorynology 1997;22:289-301.
Jones NS, Fergie N. Allergic rhinitis in children: managment guidelines. Bulletin Immunology and Allergy 2004; 3(3): 68-72.
Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006;16:148-55.
Caenen M, Hamels K, Deron P, Clement P. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRI. Rhinology 2005;43:205-09.
Moinuddin R, deTineo M, Maleckar B et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92:73-9. doi:10.1016/S1081-1206(10)61713-9
Wilson AM, Sims EJ, McFarlane LC et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598-604.
Walls RS, Heddle RJ, Tang ML, Basger BJ, Solley GO, Yeo GT. Optimising the management of allergic rhinitis: an Australian perspective. Med J Aust 2005;182:28–33.
Al Sayyad JJ, Fedorowicz Z, Alhashimi D, Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev 2007:CD003163. DOI: 10.1002/14651858.CD003163.pub4
Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999;83:153–79
Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407–13.
Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueousnasal spray. Pediatrics 2000;105:E22
Fokkens WJ, Godthelp T, Holm AF et al. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997;52:29-32.
Juliusson S, Holmberg K, Karlsson G et al. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks’ treatment with topical glucocorticoid. Clin Exp Allergy 1993;23:591-9.
DeWester J, Philpot EE, Westlund RE et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331-7.
Kaiser HB. Naclerio RM, Given J et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430-7. doi:10.1016/j.jaci.2007.02.022
Ferguson BJ. Influences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg 2004;130:617-29. doi: 10.1016/j.otohns.2004.02.001
Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58–70. doi:10.1016/j.pcrj.2005.11.002
Pullerits T, Praks L, Skoogh BE, Ani R, Lötvall J: Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med. 1999;159: 1814-1818.
Ratner PH, Howland WC, Arastu R, Philpot EE, Klein KC, Baidoo CA, Faris MA, Rickard KA: Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003;90: 536-542.doi: 10.1016/S1081-1206(10)61847-9.
Wilson AM, Orr LC, Sims EJ, Lipworth BJ: Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31: 61-68.
Small P, Kim H Allergic rhinitis Allergy Asthma Clin Immunol. 2011; 7(Suppl 1): S3. doi: 10.1186/1710-1492-7-S1-S3
Greiner A, Hellings P, Rotiroti G, Scadding G. Allergic rhinitis. Lancet 2011; 378: 2112-22. doi:10.1016/SO140-6736(11)60130-X
Carr W, Bernstein J, Lieberman P, Maltzer E, Bachert C, Price D, Munzel U, Bousquert J. A novel intranasal therapy of azelastine with fluticasone for treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10. doi: 10.1016/j.jaci.2012.01.077.
Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC, Wahn U, Bousquet J. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015 Jan-Feb;36(1):40-7. doi: 10.2500/aap.2015.36.3823.
